Scholarlink

<p>The management of rosacea continues to pose a significant clinical challenge, underscoring the necessity for alternative therapeutic strategies to address this chronic dermatological condition. The primary objective of this study was to assess the efficacy and safety of combined therapy using a 532-nm potassium titanyl phosphate (KTP) laser and a microsecond-pulsed 1064-nm neodymium-doped yttrium aluminum garnet (Nd: YAG) laser for the treatment of rosacea. A total of 15 participants underwent 3 sessions of combined laser therapy, with each session administered at 3-week intervals. Clinical evaluations were performed both before the initiation of treatment and after the completion of all 3 treatment sessions using the Clinician’s Erythema Assessment (CEA) and the Dermatology Life Quality Index (DLQI). Additionally, the Global Assessment of Improvement Scale (GAIS) was utilized to quantify overall clinical improvement, while patient-reported satisfaction levels and adverse events were documented throughout the study period. Statistical analysis revealed a significant reduction in the CEA score, which decreased from a baseline mean of 3.33 ± 0.47 to 1.47 ± 0.62 following treatment (<i>P</i> &lt; 0.001). Concurrently, the DLQI score exhibited a significant improvement, declining from 18.20 ± 2.14 at baseline to 13.80 ± 2.40 post-treatment (<i>P</i> &lt; 0.001). With regard to the GAIS, 14 out of 15 patients (93.3%) demonstrated clinical improvement; among these, 10 patients (66.7%) achieved either much or very much improvement. Notably, no severe adverse events were reported during the study. In conclusion, the findings of this study suggest that combined therapy with a 532-nm KTP laser and a microsecond-pulsed 1064-nm Nd: YAG laser represents an effective and well-tolerated treatment option for facial erythema associated with rosacea. Trial registration number was NCT07250165 (ClinicalTrials.gov) and date of registration was 18th, November, 2025, retrospectively registered.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Combined therapy of 532-nm KTP and microsecond 1064-nm Nd:YAG laser for rosacea

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月18日

查看全文
  • Yanhong Sun,
  • Yuchen Lou,
  • Limin Lao,
  • Suiqing Cai

摘要

The management of rosacea continues to pose a significant clinical challenge, underscoring the necessity for alternative therapeutic strategies to address this chronic dermatological condition. The primary objective of this study was to assess the efficacy and safety of combined therapy using a 532-nm potassium titanyl phosphate (KTP) laser and a microsecond-pulsed 1064-nm neodymium-doped yttrium aluminum garnet (Nd: YAG) laser for the treatment of rosacea. A total of 15 participants underwent 3 sessions of combined laser therapy, with each session administered at 3-week intervals. Clinical evaluations were performed both before the initiation of treatment and after the completion of all 3 treatment sessions using the Clinician’s Erythema Assessment (CEA) and the Dermatology Life Quality Index (DLQI). Additionally, the Global Assessment of Improvement Scale (GAIS) was utilized to quantify overall clinical improvement, while patient-reported satisfaction levels and adverse events were documented throughout the study period. Statistical analysis revealed a significant reduction in the CEA score, which decreased from a baseline mean of 3.33 ± 0.47 to 1.47 ± 0.62 following treatment (P < 0.001). Concurrently, the DLQI score exhibited a significant improvement, declining from 18.20 ± 2.14 at baseline to 13.80 ± 2.40 post-treatment (P < 0.001). With regard to the GAIS, 14 out of 15 patients (93.3%) demonstrated clinical improvement; among these, 10 patients (66.7%) achieved either much or very much improvement. Notably, no severe adverse events were reported during the study. In conclusion, the findings of this study suggest that combined therapy with a 532-nm KTP laser and a microsecond-pulsed 1064-nm Nd: YAG laser represents an effective and well-tolerated treatment option for facial erythema associated with rosacea. Trial registration number was NCT07250165 (ClinicalTrials.gov) and date of registration was 18th, November, 2025, retrospectively registered.